Toshali Pandey

Resident physician

UAMS primary University of Arkansas

Also affiliated: University of Arkansas Medical Center (2025); Maulana Azad Medical College (2022–2023)

2 h-index 21 pubs 15 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Toshali Pandey's research focuses on the efficacy and safety of various cancer therapies, including immune checkpoint inhibitors and chimeric antigen receptor (CAR-T) cell therapy. Her work has investigated the impact of fixed versus continuous immune checkpoint inhibitor therapy in advanced non-small cell lung cancer and explored multi-antigen CAR-T cell therapy for relapsed/refractory B cell lymphomas. Pandey has also studied peripheral blood immune cell profiling in response to BCMA CAR-T cell therapy for multiple myeloma. Additionally, her research has examined the quality of life and nutritional status of patients with corrosive-induced benign refractory esophageal strictures, as well as the impact of the COVID-19 pandemic on medical residency programs, specifically in pathology and gastroenterology training in India. She has published 21 papers with an h-index of 2 and 15 citations.

Metrics

h-index: 2
Publications: 21
Citations: 15

Positions

Resident physician publications 2024–2026

University of Arkansas for Medical Sciences Internal Medicine ORCID

Selected Publications

Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas (2026)

Frontiers in Immunology 1 citation DOI OpenAlex
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Demographic and regional trends in combined colorectal cancer and cerebrovascular disease-related mortality in the United States (1999–2023). (2026)

Journal of Clinical Oncology DOI OpenAlex
Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis. (2026)

Journal of Clinical Oncology DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

Blood Cancer Journal 2 citations DOI OpenAlex
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)

Blood DOI OpenAlex
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)

Journal of the American Society of Nephrology DOI OpenAlex
Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025)

JCO Oncology Practice DOI OpenAlex
Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review (2025)

Cancer Immunology Immunotherapy 2 citations DOI OpenAlex
MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. (2025)

Journal of Clinical Oncology DOI OpenAlex
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025)

Journal of Clinical Oncology DOI OpenAlex
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025)

Bone Marrow Transplantation DOI OpenAlex
A Case Report on Pulmonary Tumor Embolism in a Patient With a Metastatic Gastrointestinal Stromal Tumor Invading the Inferior Vena Cava: Tumor or Thrombus? (2025)

Cureus DOI OpenAlex
Simultaneous Presentation of Relapsed Diffuse Large B-cell Lymphoma and Extrapulmonary Tuberculosis in a Patient With HIV: A Case Report (2025)

Cureus DOI OpenAlex
Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience (2024)

Blood DOI OpenAlex